

Form Approved OMB No. 0920-0666 Exp. Date: xx/xx/20xx www.cdc.gov/nhsn

Complete this survey as described in the **Dialysis Event Protocol**.

**Instructions:** This survey is only for dialysis centers that provide in-center hemodialysis. If your center offers only home dialysis, please complete the Home Dialysis Center Practices Survey. Complete one survey per center. Surveys are completed for the current year. It is strongly recommended that the survey is completed in February of each year by someone who works in the center and is familiar with current practices within the center. Complete the survey based on the actual practices at the center, not necessarily the center policy, if there are differences.

*required	to save as complete				
Facility	ID #:		*Survey Year:		
ESRD	Network #:				
A. Dial	ysis Center Information				
A.1. Ge	eneral				
*1.	What is the ownership of yo	ur dialysis center? (choose one)			
	☐ Government	☐ Not for profit,	☐ For profit		
*2.	☐ Freestanding	ital affiliation of your dialysis center' □ Hospital based tal-owned, is your center affiliated w	☐ Freestanding but owned by	-	
*3.		an organization other than CMS?		′es □ N	0
*4.	☐ In-center daytime hemodialysis	vices does your center offer? (selection in-center nocturnal hemodialysis loes your center serve? (select one)  □ Pediatric only	☐ Peritoneal ☐ Home dialysis	hemodialy	sis
*5.	How many in-center hemodi	alysis stations does your center ha	ve?		
*6.		p or chain of dialysis centers? ame of the group or chain?		□ Yes	□ No
*7.	Do you (the person primarily care in the dialysis center?	responsible for collecting data for	this survey) perform patient	□ Yes	□ No
*8.	a. If yes, which best de □ Hospital-affilia □ Dialysis nurse	echnician	n charge, select all that apply)	□ Yes	□ No
*9.		r access nurse/coordinator (either f	ull or part-time) at your center?	□ Yes	□ No
collected v	with a guarantee that it will be held in stric vidual, or the institution in accordance with	vided information obtained in this surveillance syst t confidence, will be used only for the purposes sta n Sections 304, 306 and 308(d) of the Public Healt	ted, and will not otherwise be disclosed or rel h Service Act (42 USC 242b, 242k, and 242m	eased without tl (d)).	he consent
Public rep	orting burden of this collection of informati	ion is estimated to average 2.12 hours per respons	se, including the time for reviewing instructions	s, searching exi	sting data

sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333,

CDC 57.500 (Front) Rev 8, v9.2

ATTN: PRA (0920-0666).

Page 1 of 9



A.2. Iso	plation and Screeni	ng						
*10.	Does your center	have capacity	to isolate patients w	ith hepatiti	s B?			
	☐ Yes, use hepat	itis B isolation r	room ☐ Yes, us	e hepatitis	B isolation area	a □ No	hepatitis B isol	ation
*11.	Are patients routinely isolated or cohorted for treatment <u>within your center</u> for any of the following conditions? (if yes, select all that apply)						ons? (if	
	□ No, none □ Hepatitis C □ Active tuberculosis (TB disea					lisease)		
	☐ Vancomyci	n-resistant <i>Ent</i> e	erococcus (VRE)	[	☐ Clostridioides	difficile (C.	diff.)	
	☐ Methicillin-ı	esistant <i>Staph</i> y	ylococcus aureus (N	MRSA) [	☐ Other, specify	/:		
*12.	Does your center admission to your		n patients for latent	tuberculos	is infection (LTI	BI) on	☐ Yes	□ No
A.3. Pa	atient Records and	Surveillance						
*13.	-		ds of the <b>station</b> wh treatment session?		atient received	their	☐ Yes	□ No
*14.	Does your center treatment for ever		ds of the <b>machine</b> ι ssion?	ısed for ea	ch patient's hen	nodialysis	☐ Yes	□ No
*15.	If a patient from you		hospitalized, how o pital admission?	ften is you	r center able to	determine i	f a bloodstrear	n
	☐ Always	□ Often	□ Sometimes	□ Rare	ly □	] Never	□ N/A – not p	oursued
*16.	How often is your	center able to	obtain a patient's m	icrobiology	lab records fro	m a hospita	llization?	
	$\square$ Always	☐ Often	□ Sometimes	□ Rare	ly □	] Never	□ N/A – not p	oursued
*17.	Which of the follow (select all that app		in your peritoneal d	ialysis pati	ents does your	center routi	nely track?	
	☐ Peritonitis	□P	eritoneal dialysis ca	atheter site	infection $\Box$	Other (spe	ecify)	



*18.		of the following infectall that apply)	ctions in your home hemo	odialysis patie	en	ts does your center routinel	y track?	>	90 11111011
	•	dstream infection	☐ Vascular access site	infection		☐ Other (specify)	)		
<b>Please</b> (applies	respon to curre	d to the following of ent or most recent F	questions based on info ebruary relative to currer	ormation fro nt date).	m	your center for the <u>first v</u>	<u>veek of</u>	Febr	<u>uary</u>
B. Patie	ent and	staff census							
*19.	Was yo	our center operation	al during the first week of	February?			□Y	es	□ No
*20.	week o	f February?	· 	ysis <b>PATIEN</b>	ΙT	<b>S</b> were assigned to your ce	nter dur	ing th	e first
		e, indicate the numb							
		In-center hemodial							
		Home hemodialysis							
	C.	Peritoneal dialysis:							
*21.		any acute kidney inj ry?	ury (AKI) patients receive	ed hemodialy	/Si	s in your center during the f	irst wee	k of	
*22.	of Febr	uary? Include only s	staff who had direct conta	ct with dialys		rith) worked in your center d patients or equipment:			week
		-	n each of the following ca	-		Di vivi			
		Nurse/nurse assist				Dietitian:			
	b.	Dialysis patient-car		f.		Physicians/physician assist	:ant: _		
	C.	Dialysis biomedica	l technician:			Nurse practitioner:	-		
	u.	Social worker:		N.	•	Other:		2 of 9	
							rage	2019	
C. Vaco	cines								
*23.	Of the	<u>dialysis patients</u> cou	nted in question 19, how	many receiv	e (	d:			
	a.	At least 3 doses of	hepatitis B vaccine (ever	·)?	_				
	b.	The influenza (flu)	vaccine for the <u>current/m</u>	<u>ost recent</u> flu	J S	season?			
	c.	At least one dose of	of pneumococcal vaccine	(ever)?		<del></del>			
*24.	Of the	in-center hemodialy	sis patients counted in qu	uestion 19a,	hc	ow many received:			
	a.	At least 3 doses of	hepatitis B vaccine (ever	·)?	_				
	b.	The influenza (flu)	vaccine for the <u>current/m</u>	ost recent flu	J S	season?			
	c.	At least one dose of	of pneumococcal vaccine	(ever)?		<del></del>			
*25.	Of the	patient care staff me	embers counted in questi	on 21, how r	na	any received:			
		•	hepatitis B vaccine (ever						
	b.		vaccine for the <u>current/m</u>	,	- J S	season?			
*26.		our center use stan	ding orders to allow nurse ts without a specific phys	es to adminis		· · · · · · · · · · · · · · · · · · ·	□ Y	es	□ No
*27.	Which	type of pneumococo	al vaccine does your cen	iter offer to <b>p</b>	at	tients? (choose one)			
		Polysaccharide (i.e.	•	•		,			
		Conjugate (e.g., PC\	• •						
		Both polysaccharide	•						
		Neither offered							
D. Hepa	atitis B	and C							
D.1. He									



Form Approved OMB No. 0920-0666 Exp. Date: xx/xx/20xx www.cdc.gov/nhsn

*28.	Of the	MAINTE	NANCE, NON-TRA	ANSIENT <u>in-center</u> <u>hemodial</u> y	<u>ysis</u> PATIENTS from question 1	9a:	
	a.	How m	any were hepatitis	B surface <b>ANTIGEN</b> (HBsAg	) positive in the first week of Fe	bruary?	
		i.		who were hepatitis B surface any were positive when first a	<b>ANTIGEN</b> (HBsAg) positive in dmitted to your center?	the first we –	ek of
	b.	prior 12 not as	2 months ( <i>i.e., in th</i>	e past year, how many patien	ANTIGEN (HBsAg) negative to nts had newly acquired hepatitis who were antigen positive befo	B virus inf	ection;
*29.	(i.e., h		ence of resolved he	had ≥1 hemodialysis patient v patitis B infection followed by		□ Yes	□ No
D.2. H	epatitis (	С					
*30.				n hemodialysis patients for <b>he</b> te: This is NOT hepatitis B co	epatitis C antibody (anti-HCV) ore antibody)	□ Yes	□ No
*31.		your cen	•	n hemodialysis patients for he	patitis C antibody (anti-HCV)	☐ Yes	□ No
	If yes,	how freq	uently?				
		☐ Twic	e annually	$\square$ Annually	☐ Other, specify:		
*32.				ANSIENT <u>in-center</u> <u>hemodial</u> C antibody positive in the firs	<u>ysis</u> patients counted in questio t week of February?	n 19a,	
		i.		who were hepatitis C antibod en first admitted to your cente	y positive in the first week of Fer?	bruary, ho	w many
	b.	(i.e., in	the past year, how	many patients had newly acc	y negative to positive during the quired hepatitis C infection)? Do first dialyzed in your center:	not includ	

Page 3 of 9



E. Dialysis Policies and Practices						
E.1. Di	alyzer R	euse				
*33.	Does y	our center reuse dialyzers for any patients?	□ Yes	□ No		
	If yes,					
	a.	Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis patients counted in 1 them participate in dialyzer reuse?	.9a, how m	any of		
	b.	Does your center routinely test reverse osmosis (R.O.) water from the reuse room for culture and endotoxin whenever a reuse patient has a pyrogenic reaction?	☐ Yes	□ No		
	C.	Of all reused dialyzers at your center, how many undergo refrigeration prior to reprocess All	•			
	d.	Is there a limit to the number of times a dialyzer is used?  ☐ Yes (indicate number):				
		$\square$ No limit as long as dialyzer meets certain criteria (e.g., passes pressure leak test, e	tc.)			
	e.	Of all reused dialyzers in your center, how many of them have sealed (non-removable) h  ☐ All ☐ Most ☐ Some ☐ Few ☐ No		ıs?		
	f.	Where are dialyzers reprocessed?				
		☐ Dialyzers are reprocessed at our center only				
		☐ Dialyzers are transported to an off-site facility for reprocessing only				
		☐ Both at our center and off-site				
		If any dialyzers are reprocessed at the facility,				
		i. How is dialyzer header cleaning performed? (select all that apply)				
		☐ Automated machine (e.g., RenaClear® System)				
		☐ Spray device (e.g., ASSIST® header cleaner)				
		☐ Insertion of twist-tie or other instrument to break up clots				
		☐ Disassemble dialyzer to manually clean				
		☐ Other, specify:				
		☐ No separate header cleaning step performed				
		ii. How are dialyzers reprocessed?				
		☐ Automated reprocessing equipment				
		☐ Manual reprocessing				
		<u> </u>				
E.2. W	ater/Dial					
*34.		pe of dialysate is used for in-center hemodialysis patients at your center? (choose one)				
		Jltrapure				
*35.	Does y	our center routinely test the following whenever a patient has a pyrogenic reaction?				
	a.	Patient blood culture	☐ Yes	□ No		
	b.	Dialysate from the patient's dialysis machine	☐ Yes	□ No		
E.3. Pr	iming Pr	actices				
*36.	Does y	our center use hemodialysis machine Waste Handling Option (WHO) ports?	□ Yes	□ No		
*37.		y patients in your center "bled onto the machine" (i.e., where blood is allowed to reach est reach the prime waste receptacle or WHO port)?	□ Yes	□ No		



	ection P	Practices		
*38.	What fo	orm of erythropoiesis stimulating agent (ESA) is most often used in your center?		
	☐ Sing	gle-dose vial $\square$ Multi-dose vial $\square$ Pre-packaged syringe $\square$ N/A		
	a.	Is ESA from one single-dose vial or syringe administered to more than one patient?	☐ Yes	□ No
*39.	_ 	are medications <u>most commonly</u> drawn into syringes to prepare for patient administration. At the individual dialysis stations  On a mobile medication cart within the treatment area	n? (choose	e one)
		At a fixed location within the patient treatment area (e.g., at nurses' station)		
		At a fixed location removed from the patient treatment area (not a room)  In a separate medication room		
		In a pharmacy		
		Other, specify:		
*40.	Do tecl	hnicians administer any IV medications or infusates (e.g., heparin, saline) in your center?	□ Yes	□ No
*41.	What fo	orm of saline flush is most commonly used?		
		Manufacturer pre-filled saline syringes		
		Flushes are drawn from single-use saline vials		
		Flushes are drawn from multi-dose saline vials		
		Flushes are drawn from the patient's designated saline bag used for dialysis Flushes are drawn from the patient's dialysis circuit		
		Flushes are drawn from a common saline bag used for all patients		
		Other (specify):		
TE An	tibiotic l	· · · · · · · · · · · · · · · · · · ·		
E.O. AH				
*42.	Does y	our center use the following means to restrict or ensure appropriate antibiotic use?	П Уос	П Мо
	Does y	your center use the following means to restrict or ensure appropriate antibiotic use?  Have a written policy on antibiotic use	☐ Yes	□ No
	Does y a. b.	our center use the following means to restrict or ensure appropriate antibiotic use?  Have a written policy on antibiotic use  Formulary restrictions	☐ Yes	□ No
	Does y	our center use the following means to restrict or ensure appropriate antibiotic use?  Have a written policy on antibiotic use  Formulary restrictions  Antibiotic use approval process	☐ Yes ☐ Yes	□ No □ No
	Does y a. b. c. d.	Your center use the following means to restrict or ensure appropriate antibiotic use?  Have a written policy on antibiotic use  Formulary restrictions  Antibiotic use approval process  Automatic stop orders for antibiotics  r center, how often are antibiotics administered for a suspected bloodstream infection before	☐ Yes☐ Yes☐ Yes	□ No □ No □ No
*42.	Does y a. b. c. d. In your	Vour center use the following means to restrict or ensure appropriate antibiotic use?  Have a written policy on antibiotic use  Formulary restrictions  Antibiotic use approval process  Automatic stop orders for antibiotics  r center, how often are antibiotics administered for a suspected bloodstream infection beforewn (or without performing blood cultures)?	☐ Yes ☐ Yes ☐ Yes ☐ blood o	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra	Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics administered for a suspected bloodstream infection beforwing (or without performing blood cultures)?  Always □ Often □ Sometimes □ Rarely	☐ Yes☐ Yes☐ Yes	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics r center, how often are antibiotics administered for a suspected bloodstream infection before awn (or without performing blood cultures)?  Always	☐ Yes ☐ Yes ☐ Yes <u>○ re</u> blood o	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra revention Has yo	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics r center, how often are antibiotics administered for a suspected bloodstream infection before awn (or without performing blood cultures)? Always	☐ Yes ☐ Yes ☐ Yes ☐ blood o	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra  reventio  Has yo the pas	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics r center, how often are antibiotics administered for a suspected bloodstream infection before awn (or without performing blood cultures)?  Always	☐ Yes ☐ Yes ☐ Yes <u>○ re</u> blood o	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra  reventio  Has yo the pas	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics r center, how often are antibiotics administered for a suspected bloodstream infection before awn (or without performing blood cultures)? Always □ Often □ Sometimes □ Rarely on Activities  our center participated in any national or regional infection prevention-related initiatives in st year?	☐ Yes ☐ Yes ☐ Yes <u>○ re</u> blood o	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra  reventio  Has yo the pas	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics r center, how often are antibiotics administered for a suspected bloodstream infection beforewn (or without performing blood cultures)?  Always	☐ Yes ☐ Yes ☐ Yes <u>○ re</u> blood o	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra  reventio  Has yo the pas	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics recenter, how often are antibiotics administered for a suspected bloodstream infection beforms (or without performing blood cultures)? Always	☐ Yes ☐ Yes ☐ Yes <u>○ re</u> blood o	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra  reventio  Has yo the pas	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics recenter, how often are antibiotics administered for a suspected bloodstream infection before awn (or without performing blood cultures)? Always	☐ Yes ☐ Yes ☐ Yes <u>○ re</u> blood o	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra  reventio  Has yo the pas	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics center, how often are antibiotics administered for a suspected bloodstream infection before awn (or without performing blood cultures)? Always	☐ Yes ☐ Yes ☐ Yes <u>○ re</u> blood o	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra  reventio  Has yo the pas	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics recenter, how often are antibiotics administered for a suspected bloodstream infection before awn (or without performing blood cultures)? Always	☐ Yes ☐ Yes ☐ Yes <u>○ re</u> blood o	□ No □ No □ No cultures
*42.  *43.	Does y a. b. c. d. In your are dra  reventio  Has yo the pas	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics recenter, how often are antibiotics administered for a suspected bloodstream infection before awn (or without performing blood cultures)? Always	☐ Yes ☐ Yes ☐ Yes <u>○ re</u> blood o	□ No □ No □ No cultures
*42. *43.	Does y a. b. c. d. In your are dra  reventio  Has yo the pas	Have a written policy on antibiotic use Formulary restrictions Antibiotic use approval process Automatic stop orders for antibiotics recenter, how often are antibiotics administered for a suspected bloodstream infection before awn (or without performing blood cultures)? Always	☐ Yes ☐ Yes ☐ Yes <u>○ re</u> blood o	□ No □ No □ No cultures



E.6. Pr	evention Activities (continued)		
	b. If yes, is your center actively participating in any of the following prevention initiatives (sel	ect all that	apply):
	☐ CDC Making Dialysis Safer for Patients Coalition – facility-level participation		
	☐ CDC Making Dialysis Safer for Patients Coalition – corporate- or other organization-	•	ipation
	<ul> <li>☐ The Standardizing Care to improve Outcomes in Pediatric Endstage Renal Disease</li> <li>Collaborative Peritoneal Dialysis Catheter-related Infection Project</li> <li>☐ SCOPE Collaborative Hemodialysis Access-related Infection Project</li> </ul>	(SCOPE)	
	$\square$ None of the above		
*45.	In the past year, has your center's medical director participated in a leadership or educational activity as part of the American Society of Nephrology's (ASN) Nephrologists Transforming Dialysis Safety (NTDS) Initiative?	□ Yes	□ No
*46.	Does your center follow <u>CDC-recommended Core Interventions</u> to prevent bloodstream infection hemodialysis patients?	ns in	
	$\square$ Yes, all $\square$ Yes, some $\square$ No, none		
*47.	Does your center perform hand hygiene audits of staff monthly (or more frequently)?	□ Yes	□ No
*48.	Does your center perform observations of staff vascular access care and catheter accessing practices quarterly (or more frequently)?	□ Yes	□ No
*49.	Does your center perform staff competency assessments for vascular access care and catheter accessing annually (or more frequently)?	□ Yes	□ No
E.7. Pe	eritoneal Dialysis		
*50.	For <b>peritoneal dialysis catheters</b> , is antimicrobial ointment routinely applied to the exit site during dressing change?	□ Yes	□ No
	a. If yes, what type of ointment is most commonly used? (select one)		
	☐ Gentamicin		
	☐ Mupirocin		
	☐ Povidone-iodine		
	☐ Bacitracin/polymyxin B (e.g., Polysporin®)		
	☐ Bacitracin/neomycin/polymyxin B (triple antibiotic)		
	☐ Bacitracin/gramicidin/polymyxin B (Polysporin® Triple)		
	☐ Other, specify:		
F. Vas	cular Access		
F.1. Ge	eneral Vascular Access Information		
*51.	Of the MAINTENANCE, NON-TRANSIENT hemodialysis patients from question 19 (19a + 19b), received hemodialysis through each of the following access types during the first week of February		/
	a. AV fistula:		
	b. AV graft:		
	c. Tunneled central line:		
	d. Nontunneled central line:		
	e. Other vascular access device (e.g., catheter-graft hybrid):		
F.2. Ar	teriovenous (AV) Fistulas or Grafts		
*52.	Before prepping the fistula or graft site for rope-ladder cannulation, what is the site most often $\underline{c}\underline{l}$	<u>eansed</u> wi	th?
	☐ Soap and water ☐ Alcohol-based hand rub ☐ Antiseptic wipes ☐ Other, specify: _	□ N	lothing



F.2. Ar	reriovenous (AV) Fistulas or Grafts (continued)						
*53.	Before rope-ladder cannulation of a fistula or graft, what is the site most often <u>prepped</u> with?						
	(select one)						
	□ Alcohol						
	☐ Chlorhexidine without alcohol						
	☐ Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®)						
	□ Povidone-iodine (or tincture of iodine)						
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol						
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol ☐ Other specify:						
	☐ Other, specify:						
	□ Nothing						
	a. What form of this skin antiseptic is used to prep fistula/graft sites?						
	☐ Multiuse bottle (e.g., poured onto gauze)						
	☐ Pre-packaged swabstick/spongestick						
	☐ Pre-packaged pad						
	☐ Other, specify:						
	□ N/A						
*54.	How many of the fistula patients in your center undergo buttonhole cannulation?						
	□ All □ Most □ Some □ None						
	If any,						
	a. Which fistula patients undergo buttonhole cannulation?						
	☐ In-center hemodialysis patients only						
	☐ Home hemodialysis patients only						
	□ Both						
	If any in-center hemodialysis patients undergo buttonhole cannulation,						
	b. When buttonhole cannulation is performed for in-center hemodialysis patients:						
	i. Who most often performs it?						
	□ Nurse						
	☐ Patient (self-cannulation)						
	☐ Technician						
	☐ Other, specify:						
	ii. Before cannulation, what is the buttonhole site most often prepped with? (select the one most						
	commonly used)						
	☐ Alcohol						
	☐ Chlorhexidine without alcohol						
	□ Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®)						
	☐ Povidone-iodine (or tincture of iodine)						
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol						
	☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol						
	□ Other, specify:						
	□ Nothing						
	iii. Is antimicrobial ointment (e.g., mupirocin) routinely used at buttonhole ☐ Yes ☐ No						
	cannulation sites to <b>prevent</b> infection?						



	F.3. He	emodialysis Catheters					
	*55.	Before (select	accessing the hemodialysis catheter, what are the <b>catheter hubs</b> most commonly prepped with? one)				
a.		` 🗆	Alcohol				
b.			Chlorhexidine without alcohol				
c.			Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®)				
d.			Povidone-iodine (or tincture of iodine)				
e.			Sodium hypochlorite solution (e.g., Alcavis) without alcohol				
			Sodium hypochlorite solution (e.g., Alcavis) followed by alcohol				
g.			Other, specify:				
h.			Nothing				
		a.	What form of this antiseptic/disinfectant is used to prep the catheter hubs?				
			☐ Multiuse bottle (e.g., poured onto gauze)				
k.			☐ Pre-packaged swabstick/spongestick				
			□ Pre-packaged pad				
m.			□ Other, specify:				
n.			□ N/A				
0.	*56.		heter hubs routinely scrubbed after the cap is removed and before accessing the $\Box$ Yes $\Box$ No er (or before accessing the catheter via a needleless connector device, if one is used)?				
q.	*57.	commo	the catheter dressing is changed, what is the exit site (i.e., place where the catheter enters the skin) most only prepped with? (select one)				
		_	Alcohol				
S.			Chlorhexidine without alcohol				
			Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®)				
u.			Povidone-iodine (or tincture of iodine)				
V.			Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol  Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol				
W.			Other, specify:				
X.			Nothing				
у.		a.	What form of this antiseptic/disinfectant is used at the exit site?				
		a.	☐ Multiuse bottle (e.g., poured onto gauze)				
			□ Pre-packaged swabstick/spongestick				
			□ Pre-packaged pad				
			☐ Other, specify:				
			□ N/A				
	*58.	For <b>he</b> i	modialysis catheters, is antimicrobial ointment routinely applied to the exit site during dressing change?				
			$\square$ Yes $\square$ No $\square$ N/A – chlorhexidine-impregnated dressing is routinely used				
		a.	If yes, what type of ointment is most commonly used? (select one)				
			☐ Bacitracin/gramicidin/polymyxin B (Polysporin® Triple) ☐ Gentamicin				
			□ Bacitracin/polymyxin B (e.g., Polysporin®) □ Mupirocin				
			□ Bacitracin/neomycin/polymyxin B (triple antibiotic) □ Povidone-iodine				
			□ Other, specify:				
	*59.	cathete	the job classification of staff members who <u>most often</u> perform hemodialysis catheter care (i.e., access ers or perform exit site care) in your center? (select one)				
			Nurse     Technician   Other, specify:				



Form Approved OMB No. 0920-0666 Exp. Date: xx/xx/20xx www.cdc.gov/nhsn

F.3. He	emodialysis Catheters (continued)		
*60.	Are antimicrobial lock solutions u	used to <b>prevent</b> hemodialysis catheter infections in your center?	
	$\square$ Yes, for all catheter patien	nts $\square$ Yes, for some catheter patients $\square$ No	
	a. If yes, which lock solution	n is most commonly used? (select one)	
	□ Sodium citrate	□ Taurolidine	
	☐ Gentamicin	□ Ethanol	
	☐ Vancomycin	☐ Multi-component lock solution or other, specify:	_
*61.	Are needleless closed connector catheters in your center?  a. If yes, for which patients	r devices (e.g., Tego®, Q-Syte™) used on hemodialysis ☐ Yes ☐ N	10
	<ul><li>☐ In-center hemodialys</li><li>☐ Home hemodialysis</li><li>☐ Both</li></ul>	·	
*62.	☐ Chlorhexidine dressing ☐ Other antimicrobial dre Antiseptic-impregnated of ☐ 3M™ Curos™ Disin☐ ClearGuard® HD e	·	
		ated hemodialysis catheters	
	☐ None of the above		
*63.	<ul><li>a. Do you provide catheter patier center?</li></ul>	nts with supplies to allow for changing catheter dressings outside the dialysis	
	☐ Yes, routinely	$\square$ Yes, only in certain circumstances $\square$ No	
	b. Do you provide catheter patier Shield®, Cath Dry™) to allow the	nts with a protective catheter cover (e.g. Catheter Shower Cover by Shower em to shower?	
	☐ Yes, routinely	$\square$ Yes, only in certain circumstances $\square$ No	
Comme	ents:		

Disclaimer: Use of trade names and commercial sources is for identification only and does not imply endorsement.